Process development · preclinical planning · Neonatal respiratory care
SAWASURF™
SawaSurf is our effort to produce bovine pulmonary surfactant closer to premature newborns who need it—through local sourcing, pharmaceutical purification and regional manufacture, with a lyophilised presentation as a development target.
Programme:
SawaSurf™
Focus:
Neonatal respiratory care
Current stage:
Early feasibility
Status:
Process development · preclinical planning
No mother should watch her newborn fight for every breath because the medicine that could help is too far away—or too expensive.
Premature lungs may not yet make enough surfactant to stay open. The therapy exists. But when it is imported, refrigerated and priced too far out of reach, access can fail the babies who need it most.

Made closer, so more babies can breathe.
SawaSurf is our effort to produce bovine pulmonary surfactant closer to premature newborns who need it—through local sourcing, pharmaceutical purification and regional manufacture, with a lyophilised presentation as a development target.
For neonatal clinicians, bioprocess researchers, manufacturers and health-system partners.
What progress could unlock.
These are the outcomes guiding development. Product claims will follow the evidence generated at the appropriate stage.
Reduce dependence on imported, refrigerated products
Create a path toward more reliable and affordable access
Build African manufacturing capability for an essential neonatal therapy
Emotion opens the door. Evidence keeps us honest.
These sources support the clinical category or scientific rationale. They do not establish product-specific safety, efficacy or regulatory approval for SawaSurf.
Where SawaSurf stands today.
Current stage: Early feasibility
Feasibility, process development and preclinical planning

